Insider Selling: Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Director Sells 8,212 Shares of Stock

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Get Free Report) Director Barry D. Quart sold 8,212 shares of the firm's stock in a transaction dated Tuesday, June 10th. The stock was sold at an average price of $30.36, for a total transaction of $249,316.32. Following the completion of the transaction, the director now directly owns 12,546 shares in the company, valued at $380,896.56. This represents a 39.56% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Kiniksa Pharmaceuticals Trading Up 2.1%

NASDAQ:KNSA traded up $0.57 during midday trading on Friday, hitting $28.30. 907,293 shares of the stock were exchanged, compared to its average volume of 516,217. Kiniksa Pharmaceuticals, Ltd. has a one year low of $17.38 and a one year high of $30.69. The company has a market capitalization of $2.07 billion, a price-to-earnings ratio of -202.13 and a beta of 0.06. The business has a 50-day moving average price of $25.12 and a two-hundred day moving average price of $22.17.

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) last announced its earnings results on Tuesday, April 29th. The company reported $0.11 EPS for the quarter, topping the consensus estimate of $0.02 by $0.09. The firm had revenue of $137.79 million for the quarter, compared to analysts' expectations of $128.35 million. Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. The firm's quarterly revenue was up 72.5% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.25) earnings per share. Sell-side analysts forecast that Kiniksa Pharmaceuticals, Ltd. will post -0.55 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on KNSA shares. Jefferies Financial Group lifted their price target on Kiniksa Pharmaceuticals from $40.00 to $45.00 and gave the company a "buy" rating in a report on Tuesday, April 29th. Wall Street Zen raised Kiniksa Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Saturday. Citigroup started coverage on Kiniksa Pharmaceuticals in a report on Thursday, March 13th. They set a "buy" rating and a $40.00 price target on the stock. Finally, Wedbush reaffirmed an "outperform" rating and set a $34.00 price target on shares of Kiniksa Pharmaceuticals in a report on Wednesday, April 16th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Kiniksa Pharmaceuticals presently has an average rating of "Buy" and a consensus target price of $38.80.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Nuveen Asset Management LLC grew its position in Kiniksa Pharmaceuticals by 7.3% in the fourth quarter. Nuveen Asset Management LLC now owns 795,612 shares of the company's stock worth $15,737,000 after buying an additional 54,361 shares during the last quarter. Wellington Management Group LLP grew its position in Kiniksa Pharmaceuticals by 46.3% in the fourth quarter. Wellington Management Group LLP now owns 69,813 shares of the company's stock worth $1,381,000 after buying an additional 22,096 shares during the last quarter. Charles Schwab Investment Management Inc. grew its position in Kiniksa Pharmaceuticals by 36.1% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 122,019 shares of the company's stock worth $2,414,000 after buying an additional 32,393 shares during the last quarter. Raymond James Financial Inc. acquired a new position in Kiniksa Pharmaceuticals in the fourth quarter worth approximately $3,955,000. Finally, Globeflex Capital L P grew its position in Kiniksa Pharmaceuticals by 217.1% in the fourth quarter. Globeflex Capital L P now owns 88,596 shares of the company's stock worth $1,752,000 after buying an additional 60,656 shares during the last quarter. Institutional investors and hedge funds own 53.95% of the company's stock.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.